{"id":154252,"date":"2021-01-20T01:13:20","date_gmt":"2021-01-20T06:13:20","guid":{"rendered":"https:\/\/www.immortalitymedicine.tv\/eledon-pharmaceuticals-to-participate-in-the-virtual-noble-capital-markets-seventeenth-annual-investor-equity-conference\/"},"modified":"2024-08-18T11:43:00","modified_gmt":"2024-08-18T15:43:00","slug":"eledon-pharmaceuticals-to-participate-in-the-virtual-noble-capital-markets-seventeenth-annual-investor-equity-conference","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/global-news-feed\/eledon-pharmaceuticals-to-participate-in-the-virtual-noble-capital-markets-seventeenth-annual-investor-equity-conference.php","title":{"rendered":"Eledon Pharmaceuticals to Participate in the Virtual Noble Capital Markets&#8217; Seventeenth Annual Investor \/ Equity Conference"},"content":{"rendered":"<p><![CDATA[IRVINE, Calif., Jan.  19, 2021  (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (\u201cEledon\u201d) (NASDAQ: ELDN), a clinical stage biopharmaceutical company focused on developing life-changing, targeted medicines for persons undergoing organ or cellular transplantation, as well as those living with immunological diseases, today announced that David-Alexandre C. Gros, MD, Chief Executive Officer, will be participating in the virtual Noble Capital Markets' Seventeenth Annual Investor \/ Equity Conference. Mr. Gros is scheduled to present at 9:00am ET on Wednesday, January 20 \u2013 Track 1.]]><\/p>\n<p>Read the original post:<br \/>\n<a target=\"_blank\" rel=\"nofollow noopener\" href=\"http:\/\/www.globenewswire.com\/news-release\/2021\/01\/19\/2161074\/0\/en\/Eledon-Pharmaceuticals-to-Participate-in-the-Virtual-Noble-Capital-Markets-Seventeenth-Annual-Investor-Equity-Conference.html?f=22&amp;fvtc=5&amp;fvtv=46634288\" title=\"Eledon Pharmaceuticals to Participate in the Virtual Noble Capital Markets' Seventeenth Annual Investor \/ Equity Conference\">Eledon Pharmaceuticals to Participate in the Virtual Noble Capital Markets' Seventeenth Annual Investor \/ Equity Conference<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":64,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[1246886],"tags":[],"class_list":["post-154252","post","type-post","status-publish","format-standard","hentry","category-global-news-feed"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/154252"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/64"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=154252"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/154252\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=154252"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=154252"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=154252"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}